MetaCap

Autolus Therapeutics (AUTL) vs Editas Medicine (EDIT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Autolus Therapeutics (AUTL) has outperformed Editas Medicine (EDIT) over the past year, losing 26.2% versus a loss of 32.2%. Over five years, AUTL leads with a -85.5% price change compared with -94.9% for EDIT. Editas Medicine is the larger company by market cap ($253.1 million vs $241.7 million), about 1.0 times the size, while Autolus Therapeutics is growing revenue faster (+644.9% vs +25.4%).

Autolus Therapeutics converts more of its revenue into profit, with a net margin of -381.4% versus -395.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AUTL-26.24%EDIT-32.23%
+113%+37%-39%
Nov 21, 20251 yearNov 20, 2026
AUTL-85.41%EDIT-95.36%
+21%-41%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AUTL versus EDIT key metrics
MetricAUTLEDIT
Share price$0.9073$1.64
Market cap$241.65M$253.12M
1-day change-7.38%-4.09%
YTD return-54.41%-20.00%
1-year return-26.24%-32.23%
5-year return-85.51%-94.93%
EPS (TTM)$-0.96$-0.54
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$75.39M$40.52M
Revenue growth (YoY)+644.94%+25.39%
Net income (latest FY)$-287.53M$-160.06M
Gross margin-27.83%—
Operating margin-358.87%-394.89%
Net margin-381.40%-395.01%
52-week high$2.58$3.94
52-week low$0.896$1.63
Distance from 52-week high-64.83%-58.38%
Analyst consensusstrong_buybuy
Avg. price target upside+821.42%+271.95%
Average volume2.07M2.63M
Shares outstanding266.34M154.34M
Employees75287
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Autolus Therapeutics is more profitable, keeping -381.4 cents of every revenue dollar as net income versus -395.0 cents for Editas Medicine.
  • Autolus Therapeutics grew revenue faster in its latest fiscal year (+644.94% vs +25.39%).

About Autolus Therapeutics

AUTL stock →

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 752 employees

About Editas Medicine

EDIT stock →

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 87 employees

AUTL vs EDIT FAQ

Which is bigger, Autolus Therapeutics or Editas Medicine?

Editas Medicine (EDIT) is larger, with a market capitalization of $253.12M compared with $241.65M for Autolus Therapeutics (AUTL).

Which stock has performed better over the past year, AUTL or EDIT?

AUTL returned -26.24% over the past 12 months, compared with -32.23% for EDIT (price return, excluding dividends). Past performance does not predict future results.

Are Autolus Therapeutics and Editas Medicine in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons